Abstract:The coronavirus disease 2019 (COVID-19) pandemic caused extensive loss of life worldwide. Further, the COVID-19 and influenza mix-infection had caused great distress to the diagnosis of the disease. To control illness progression and limit viral spread within the population, a real-time reverse-transcription PCR (RT-PCR) assay for early diagnosis of COVID-19 was developed, but detection was time-consuming (4-6 h). To improve the diagnosis of COVID-19 and influenza, we herein developed a recombinase polymerase amplification (RPA) method for simple and rapid amplification of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19 and Influenza A (H1N1, H3N2) and B (influenza B). Genes encoding the matrix protein (M) for H1N1, and the hemagglutinin (HA) for H3N2, and the polymerase A (PA) for Influenza B, and the nucleocapsid protein (N), the RNA-dependent-RNA polymerase (RdRP) in the open reading frame 1ab (ORF1ab) region, and the envelope protein (E) for SARS-CoV-2 were selected, and specific primers were designed. We validated our method using SARS-CoV-2, H1N1, H3N2 and influenza B plasmid standards and RNA samples extracted from COVID-19 and Influenza A/B (RT-PCR-verified) positive patients. The method could detect SARS-CoV-2 plasmid standard DNA quantitatively between 10(2) and 10(5) copies/ml with a log linearity of 0.99 in 22 min. And this method also be very effective in simultaneous detection of H1N1, H3N2 and influenza B. Clinical validation of 100 cases revealed a sensitivity of 100% for differentiating COVID-19 patients from healthy controls when the specificity was set at 90%. These results demonstrate that this nucleic acid testing method is advantageous compared with traditional PCR and other isothermal nucleic acid amplification methods in terms of time and portability. This method could potentially be used for detection of SARS-CoV-2, H1N1, H3N2 and influenza B, and adapted for point-of-care (POC) detection of a broad range of infectious pathogens in resource-limited settings.

Sensitive and Rapid Diagnosis of Respiratory Virus Coinfection Using a Microfluidic Chip‐Powered CRISPR/Cas12a System

Sensitive and Rapid Diagnosis of Respiratory Virus Coinfection Using a Microfluidic Chip‐Powered CRISPR/Cas12a System (Small 26/2022)

Application of Multiplex PCR Coupled with Matrix-Assisted Laser Desorption Ionization–Time of Flight Analysis for Simultaneous Detection of 21 Common Respiratory Viruses

CRISPR/Cas12a-Assisted isothermal amplification for rapid and specific diagnosis of respiratory virus on an microfluidic platform

An integrated dual-layer microfluidic platform for multiple respiratory viruses screening

Development of a rapid, sensitive detection method for SARS‐CoV‐2 and influenza virus based on recombinase polymerase amplification combined with CRISPR‐Cas12a assay

Rapid and Accurate Detection of SARS-CoV-2 Using an Ipad-Controlled, High-Throughput, Portable, and Multiplex Hive-Chip Platform (Hicube).

Development of a multi-recombinase polymerase amplification assay for rapid identification of COVID-19, influenza A and B

Rapid detection of SARS-CoV-2 with CRISPR-Cas12a

Detection and identification of SARS-CoV-2 and Influenza A based on microfluidic technology

Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants

A High-Throughput, Multi-Index Isothermal Amplification Platform for Rapid Detection of 19 Types of Common Respiratory Viruses Including SARS-CoV-2

Point-of-Care Multiplex Detection of Respiratory Viruses

Portable and simultaneous detection of four respiratory pathogens through a microfluidic LAMP and real-time fluorescence assay

Rapid Differential Diagnosis of Seven Human Respiratory Coronaviruses Based on Centrifugal Microfluidic Nucleic Acid Assay

Simultaneous Detection of Multiple Respiratory Pathogens Using an Integrated Microfluidic Chip

A Digital Microfluidic RT-qPCR Platform for Multiple Detections of Respiratory Pathogens

High-Throughput and Integrated CRISPR/Cas12a-Based Molecular Diagnosis Using a Deep Learning Enabled Microfluidic System

Multiplexed Detection of Respiratory Pathogens with a Portable Analyzer in a “Raw-Sample-in and Answer-Out” Manner

An automated nucleic acid detection platform using digital microfluidics with an optimized Cas12a system

Low-Cost and Scalable Platform with Multiplexed Microwell Array Biochip for Rapid Diagnosis of COVID-19